


MAKING IRELAND A EUROPEAN LEADER IN CLINICAL RESEARCH 2025

efficient clinical research system to compete internationally and to attract clinical trials. IPHA has collaborated with the State Claims Agency and HSE in the

It is essential that Ireland has a predictable, transparent and

- creation of the standard Clinical Trial Indemnity Form and model Clinical Trial Agreement, which have substantially improved the start-up efficiency of clinical trials. IPHA welcomes the work of the National Clinical Trials Oversight Group,
- and urges this work to continue so that patients in Ireland can be included in life changing clinical trials.

IRELAND



More companies choose Denmark than Ireland to conduct clinical

research.

DENMARK

Between 2023 and 2024, Ireland started* 75 pharmaceutical industry sponsored clinical trials compared to Denmark which started 229⁽³⁾.

*The clinical trial start date on CTIS refers to the date when recruitment for the clinical trial is opened in the Member State concerned. For pharmaceutical industry sponsored clinical trials that began in both countries (n=42) between 2022 & 2024, Irish

planned patient numbers were 362 compared to Denmark,







compared to 2023 (67 days) $^{(3)}$. 2023 2024 400 350

For pharmaceutical industry sponsored clinical trials with an Irish

start date of either 2023 or 2024, there were 773 patients

The average time to first patient in** reduced by 31% in 2024 (46 days)

expecting to access one of the 75 clinical trials (3).

300



We have a strong base of international biopharmaceutical


companies, alongside global clinical leaders, and a willing and

sponsored clinical trials being conducted per capita (100,000), based on 2024 data⁽³⁾.

adaptive policymaker community.

However, Ireland lags behind 17 of 27 European countries, ranking 18th, in relation to the number of pharmaceutical industry

3.00 2.50



Ireland is a hub for biological medicines manufacturing. We can be a leader in clinical research, too. Let's all work together for patients.



DATA SOURCES 1. Eurostat, 2024

3. Clinical Trials Information System (CTIS) For further information and recommendations please refer to

the IPHA Clinical Trials Activity Comparison Report 2025.

2. The World Bank, data.worldbank.org, 2023